FARAPULSE™ Pulsed Field Ablation is here.
Atrial fibrillation (AFib) doesn’t just disrupt your patients’ hearts. It disrupts their lives. Get them back to the beat they were born with, safely and effectively.
Over 125,000 patients have been treated with FARAPULSE.1 It’s the #1 doctor-recommended Pulsed Field Ablation (PFA) procedure worldwide.1
FARAPULSE PFA is transforming cardiac ablation for your patients.
FARAPULSE PFA is the next generation of cardiac ablation approved to treat drug-refractory, paroxysmal AFib. This minimally invasive procedure uses short pulses of electrical energy to precisely target the areas in the heart that cause an irregular heartbeat, while minimizing damage to collateral structures close to the heart, such as the esophagus. The FARAPULSE PFA procedure can significantly reduce, or even eliminate episodes of paroxysmal AFib for many patients.2*
The longer AFib is not adequately managed with medication, the greater the risk patients have of developing persistent AFib or permanent AFib.3
Talking with your patients about FARAPULSE PFA.
Discussing treatment options can be uncomfortable for your drug-refractory patients, especially when it comes to procedures like cardiac ablation. FARAPULSE PFA helps simplify the conversation by offering clear benefits that are easy for patients to understand and appreciate.
94% of patients said they were satisfied with the FARAPULSE PFA procedure.1
In a real-world clinical study, 8 out of 10 people with paroxysmal AFib had no returning symptoms within 1 year of their FARAPULSE PFA procedure.2*
7 out of 10 FARAPULSE PFA patients remained atrial arrhythmia free and off of heart rhythm medications at one year.4
FARAPULSE PFA had a shorter, more predictable procedure time than traditional thermal ablation5 and only required one day or less average hospital stay.2*
In a real-world study of 17,000 patients, the FARAPULSE PFA procedure had a less than 1% rate of procedural complications.5
FARAPULSE is the world's most studied FDA-approved PFA procedure,1 and in a randomized clinical trial had a less than 2.1% rate of complications.6
FARAPULSE is the world’s most studied FDA-approved PFA system.1
With over 55 clinical trials completed and ongoing, 150+ publications and the largest safety registry of any PFA device.
FARAPULSE uses heart-friendly technology to deliver the energy pulses that target AFib.
The FARAPULSE procedure is designed to turn disrupted into uninterrupted.
When you start a day and you see that several cases are planned with FARAPULSE, you feel relaxed upfront because of the intriguing safety profile of pulsed field ablation. Also important besides safety is the comfort, and you know for the first time patients are asking me the day after the procedure, “Doctor, did you really treat me yesterday because I feel nothing?" This was never said to me using thermal energy.
Professor Mattias Duytschaever
Electrophysiologist
If medications aren’t working, there is the potential to reduce AFib recurrence with the FARAPULSE PFA procedure.
References:
1. BSC data on file. 2024.
2. Turagam MK, Neuzil P, Schmidt B, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023;148(1):35–46.
3. Poole JE, Bahnson TD, Monahan KH, Johnson G, Rostami H, Silverstein AP, Al-Khalidi HR, Rosenberg Y, Mark DB, Lee KL, Packer DL; CABANA Investigators and ECG Rhythm Core Lab. Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. J Am Coll Cardiol. 2020 Jun 30;75(25):3105–3118. doi: 10.1016/j.jacc.2020.04.065. PMID: 32586583; PMCID: PMC8064404.
4. Reddy VY, Gerstenfeld EP, Natale A, et al., Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. New England Journal of Medicine. 2023;Nov2;389(18):1660–1671. doi:10.1056/NEJMoa2307291
5. Ekanem, E, Neuzil, P, Reichlin, T, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med 30, 2020–2029 (2024). https://doi.org/10.1038/s41591-024-03114-3
6. ReddyV, Lehmann JW, Gerstenfeld EP, et al. A randomized controlled trial of pulsed field ablation versus standard-of-care ablation for paroxysmal atrial fibrillation: The ADVENT trial rationale and design. Heart Rhythm 2023;4(5):317-328. doi 10.1016/j.hroo.2023.03.001
* In a clinical trial 81.6% of people with paroxysmal AFib had no atrial fibrillation, atrial flutter, or atrial tachycardia after a single ablation procedure at 12 months.